Why might codeine be ineffective in poor CYP2D6 metabolizers, and what are the clinical implications for analgesia?

• A. Codeine requires CYP2D6 to convert to morphine; poor metabolizers have little active drug; alternative analgesics should be used.
• B. Codeine does not require CYP2D6 for activation, so metabolism status does not affect analgesia.
• C. In poor metabolizers, codeine produces more morphine leading to toxicity.
• D. All patients respond the same due to alternative metabolites.

Answer: (A)

Codeine is a prodrug that relies on the liver enzyme CYP2D6 to be converted into morphine, the form that provides most of codeine’s pain relief. When someone is a poor CYP2D6 metabolizer, that conversion is inefficient, so only small amounts of morphine are produced. With less active morphine circulating, the analgesic effect of codeine is minimal, and pain relief is inadequate. Clinically, this means codeine may not be effective for such patients, and it’s wise to choose an analgesic that doesn’t depend on CYP2D6 activation—such as an opioid like morphine or another non-CYP2D6-activated analgesic—or use non-opioid options as appropriate. It’s also worth noting that metabolic status varies across individuals, with ultrarapid metabolizers at risk for morphine toxicity, highlighting the need for genotype or phenotype awareness when selecting analgesics.